It was a pleasure to welcome Greg Vladimer, Co-Founder and CEO of GraphTx, at AITHYRA. Greg gave a seminar on “The techbio path: how scientists build companies”, shared his valuable experience as entrepreneur and immunologist, and gave input on his lessons learned in academia and industry.
Greg attended the UMass Chan Medical School, where he obtained a PhD in immunology. He did a postdoc at CeMM with a research focus on drug discovery for blood cancers. As a co-founder of the CeMM spin-off Allcyte, he co-led the company's $60M exit and subsequent $510M IPO of Exscientia. In 2024 he co-founded Graph Therapeutics, a next-generation techbio company developing an AI-powered platform to bring the precision medicine paradigm to inflammation and immunology drug discovery.
We greatly appreciate Greg for his work in AI-driven drug discovery platforms, his innovative approach to healthcare, his personal-drive and ability to motivate others, and also paving the way for LGBTQ+ scientists, entrepreneurs and C-suites. Thanks for spending your time with us!
#AithyraTalk #GraphTx
